WELLlife™

COVID-19 / Influenza A&B Test

The WELLlife™ COVID-19 / Influenza A&B Test differentiates between SARS-COV-2, Influenza A and Influenza B infection with a single test.

WELLlife™ COVID-19 / Influenza A&B Home Test

Features and Benefits

- **Ease of use**
  Differentiate between SARS-COV-2, Influenza A, and Influenza B infections with an easy nasal swab.
- **Rapid & Convenient**
  Results are available in just 10 minutes, with kits that can be stored in 36°F-86°F (2°C-30°C), allowing testing anytime and anywhere.
- **Reliable**
  The test demonstrates outstanding clinical performance, providing trustworthy results.
- **Extended Detection Window**
  Has a broader detection window within five (5) days of symptom onset.

WELLlife™ COVID-19 / Influenza A&B POC Test

Features and Benefits

- **Cost-effective**
  Differentiate between SARS-COV-2, Influenza A, and Influenza B infections with a single test.
- **Rapid**
  Results available in 10 minutes allow for testing and treatment during the same office visit.
- **Quality Assurance**
  The outstanding clinical performance, including built-in kit controls for external quality testing, enables physicians to make quicker and more confident decisions.
- **Extended Detection Window**
  Offers a broader detection window for differential diagnosis and treatment within five (5) days of symptom onset.

Ordering Information

Item Code	Description	Size	Intended Use
WV01P0001	WELLlife™ COVID-19 / Influenza A&B Home Test	2T/Kit	Over-the-counter (OTC) Use
WV01P0002	WELLlife™ COVID-19 / Influenza A&B Test	25T/Kit	For professional use

In the USA, this product has not been FDA cleared or approved, but has been authorized by FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/ or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Rel.: 2024/09/30

+1 (630) 468-2199 || info@wondfousa.com || **WondfoUSA.com**

Wondfo® || bringing science to life